<SEC-DOCUMENT>0001213900-21-051263.txt : 20211004
<SEC-HEADER>0001213900-21-051263.hdr.sgml : 20211004
<ACCEPTANCE-DATETIME>20211004080034
ACCESSION NUMBER:		0001213900-21-051263
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20211004
FILED AS OF DATE:		20211004
DATE AS OF CHANGE:		20211004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		211301049

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea148326-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of: October 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>ENLIVEX THERAPEUTICS LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(1):&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(7):&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October 4, 2021, Enlivex Therapeutics Ltd.,
a company organized under the laws of the State of Israel (the &ldquo;Company&rdquo;), issued a press release announcing the peer-reviewed
publication of clinical data from the Company&rsquo;s Phase Ib sepsis trial in <I>Frontiers in Immunology, </I>a leading journal in its
field publishing rigorously peer-reviewed research articles. A copy of such press release is furnished as Exhibit 99.1 to this Report
on Form 6-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%"><A HREF="ea148326ex99-1_enlivex.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">Press Release issued by Enlivex Therapeutics Ltd. on October 4, 2021.</U></FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex Therapeutics Ltd.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:</P></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz<BR>
Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: October 4, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea148326ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON OCTOBER 4, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enlivex
Announces the Peer-Reviewed Publication in <I>Frontiers in Immunology</I> of Clinical Data from Phase Ib Trial Evaluating Allocetra in
Patients with Sepsis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Data
published in Frontiers in Immunology show a robust safety profile and substantial improvements in state of organ failure, duration of
ICU stay, and mortality in 10 Allocetra-treated severe sepsis patients vs. matched historical controls</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nes-Ziona,
Israel, October 4, 2021 (GLOBE NEWSWIRE) </B>&ndash; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;), a clinical-stage
macrophage reprogramming immunotherapy company, today announced the peer-reviewed publication of clinical data from the Company&rsquo;s
Phase Ib sepsis trial in <I>Frontiers in Immunology, </I>a leading journal in its field publishing rigorously peer-reviewed research
articles. The paper, entitled &ldquo;Apoptotic Cells for Therapeutic Use in Cytokine Storm Associated With Sepsis &ndash; A Phase Ib
Clinical Trial&rdquo; was published in collaboration with researchers at Hadassah-Hebrew University Medical Center and The Wohl Institute
for Translational Medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
presented in the paper compared 10 patients admitted to the intensive care unit (ICU) with sepsis who were treated with Allocetra<SUP>TM
</SUP>plus standard-of-care with 37 matched controls with sepsis who received only standard-of-care treatment at the same hospital from
2014-2019. Control patients were matched by age, gender, severity of the septic condition reflected by Sequential Organ Failure Assessment
(SOFA) score, and infection source. The clinical trial was conducted at Hadassah Medical Center, which is one of the largest and most
prestigious hospitals in Israel.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
believe that this peer-reviewed publication provides important external validation for Allocetra<SUP>TM</SUP> and its broadly applicable
mechanism of action (MOA) in bacterial systemic infections ,&rdquo; said Prof. Dror Mevorach, M.D., Chief Scientific Officer of Enlivex
and lead author of the study. &ldquo;Compared to matched controls, patients with severe sepsis treated with Allocetra<SUP>TM</SUP>&nbsp;experienced
substantial improvements in state of organ failure, duration of ICU stay, and mortality. Exploratory analyses suggest that these improvements
were due to Allocetra&rsquo;s ability to resolve heterogenous cytokine storms by reprogramming macrophages through the modulation of
multiple immune pathways. We believe this immunotherapeutic MOA positions Allocetra<SUP>TM</SUP> to address critical unmet needs not
only in sepsis, which currently has no specific pharmacologic treatments, but also in other conditions linked to non-homeostatic macrophages
such as cancer and acute respiratory distress syndrome associated with COVID-19.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
data and conclusions from the paper include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocetra-treated
patients (N=10) had a mortality rate of 0% at the end of the study&rsquo;s 28-day follow-up period compared to a mortality rate of 27%
in matched historical controls (N=37).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocetra-treated
patients exhibited rapid resolution of organ dysfunction and had significantly shorter ICU stays compared to matched controls (p &lt;
0.0001).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
patients had elevated pro- and anti-inflammatory cytokines, chemokines, and additional immune modulators that steadily decreased following
Allocetra<SUP>TM</SUP> treatment.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
serious related adverse events or definite treatment-related adverse events were reported with Allocetra<SUP>TM</SUP> treatment.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocetra<SUP>TM
</SUP>is currently being evaluated in patients with pneumonia-associated sepsis in a randomized, placebo-controlled Phase IIb trial and
in COVID-19 patients with acute respiratory distress syndrome in a separate randomized, placebo-controlled Phase IIb trial. Top-line
data from both trials are expected in the second quarter of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
THE PHASE Ib SEPSIS STUDY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aim of this study was to determine the safety, tolerability and efficacy of Allocetra<SUP>TM</SUP>&nbsp;in subjects admitted to the ICU
with sepsis. Allocetra<SUP>TM</SUP>&nbsp;(140 x 10<SUP>6</SUP>&nbsp;cells/kg) was administered in either a single dose to 6 patients
at day 1 or in two doses to 4 additional patients at days 1 and 3. Patients were followed for 28 days. The study subjects were also compared
to historical controls hospitalized in the ICU, matched by age, gender, SOFA score, and infection source.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
ALLOCETRA<SUP>TM</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocetra<SUP>TM</SUP>&nbsp;is
being developed as a universal, off-the-shelf cell therapy designed to&nbsp;reprogram macrophages. Diseases such as solid cancers, sepsis,
COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly
to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra<SUP>TM</SUP>&nbsp;has the potential to provide
a novel immunotherapeutic mechanism of action&nbsp;for life-threatening clinical indications that are defined as &ldquo;unmet medical
needs&rdquo;, as a stand-alone therapy or in combination with leading therapeutic agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
ENLIVEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex
is a clinical stage immunotherapy company developing Allocetra<SUP>TM</SUP>, a universal, off-the-shelf cell therapy designed
to&nbsp;reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is
critical for immune system rebalancing and resolution of life-threatening conditions. For more information,
visit&nbsp;http://www.enlivex.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT><I>Safe Harbor Statement:&nbsp; This press release contains forward-looking statements,
which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo; &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo; &ldquo;would&rdquo;,
&ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;has the potential to&rdquo; and
other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of
current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for,
ALLOCETRA<SUP>TM</SUP>&nbsp;programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.&nbsp; Investors are cautioned that forward-looking statements involve risks and
uncertainties that may affect Enlivex&rsquo;s business and prospects, including the risks that Enlivex may not succeed in generating
any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results
or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications
being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks
and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of
clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals.
The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development
of any products using the ALLOCETRA<SUP>TM</SUP>&nbsp;product line could also be affected by a number of other factors, including
unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact
of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other
proprietary rights held by competitors and other third parties.&nbsp; In addition to the risk factors described above, investors
should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex&rsquo;s filings with
the Securities and Exchange Commission, including in the Company&rsquo;s most recent Annual Report on Form 20-F filed with the
Securities and Exchange Commission.&nbsp; The forward-looking statements contained in this press release speak only as of the date
the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under
applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENLIVEX
CONTACT</B><BR>
Shachar Shlosberger, CFO<BR>
Enlivex Therapeutics, Ltd.<BR>
shachar@enlivexpharm.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR
RELATIONS CONTACT</B><BR>
Eric Ribner<BR>
LifeSci Advisors<BR>
eric@lifesciadvisors.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "6 / # 2(  A$! Q$!_\0
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MI!4D$<@CM7KFK#_A-?AG'?*-U[;+YI Z[TX<?B.?RKR.NV^'?BB+1;^2PO9
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4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
